Thanks largely to news of a crucial legal settlement, GSK (NYSE: GSK) was one of the better-performing big pharma stocks on ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

GSK plc (NYSE:GSK – Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 10,740,675 shares changed hands during mid-day trading, an increase of 196% from the previous ...

GSK has an average analyst rating of buy and is -11.86% away from its mean target price of $45.88 per share Its trailing ...

GSK has reached agreements with 10 plaintiff firms to settle around 80,000 state court product liability cases related to its heartburn medication, Zantac, for $2.2 billion.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.

(Alliance News) - GSK PLC on Wednesday agreed to pay up to USD2.2 billion to settle the vast majority of cases linked to its heartburn medicine Zantac.

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.

GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac ...

GSK said Wednesday that it is paying up to $2.2 billion to resolve 93% of its US state-based liability cases related to its ...